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Abstract
Background: The COVID-19 pandemic has introduced further challenges into Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) decisions.
Existing evidence suggests success rates for CPR in COVID-19 patients is low and the risk to healthcare professionals from this aerosol-generating
procedure complicates the benefit/harm balance of CPR.
Methods: The study is based at a large teaching hospital in the United Kingdom where all DNACPR decisions are documented on an electronic
healthcare record (EHR). Data from all DNACPR/TEAL status forms between 1st January 2017 and 30th April 2020 were collected and analysed. We
compared patterns of decision making and rates of form completion during the 2-month peak pandemic phase to an analogous period during 2019.
Results: A total of 16,007 forms were completed during the study period with a marked increase in form completion during the COVID-19 pandemic.
Patients with a form completed were on average younger and had fewer co-morbidities during the COVID-19 period than in March-April 2019. Several
questions on the DNACPR/TEAL forms were answered significantly differently with increases in patients being identified as suitable for CPR (23.8%
versus 9.05%; p < 0.001) and full active treatment (30.5% versus 26.1%; p = 0.028). Whilst proportions of discussions that involved the patient remained
similar during COVID-19 (95.8% versus 95.6%; p = 0.871), fewer discussions took place with relatives (50.6% versus 75.4%; p < 0.001).
Conclusion: During the COVID-19 pandemic, the emphasis on senior decision making and conversations around ceilings of treatment appears to have
changed practice, with a higher proportion of patients having DNACPR/TEAL status documented. Understanding patient preferences around life-
sustaining treatment versus comfort care is part of holistic practice and supports shared decision making. It is unclear whether these attitudinal changes
will be sustained after COVID-19 admissions decrease.
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Introduction
Cardiopulmonary resuscitation (CPR) is a potentially life-saving
intervention for patients who go into cardiac arrest. It involves the
provision of airway manoeuvres, artificial ventilation, external chest
compressions, and, in some cases, electrical defibrillation, until further
interventions can be implemented to help return of spontaneous
circulation (ROSC). CPR is an appropriate intervention in the case of
sudden cardiac arrest in ‘shockable’ ventricular arrythmias (often due
to acute myocardial ischaemia), but is less successful in cardiac
arrests due to other causes which lead to ‘non-shockable’ rhythms.1,2
Distinguishing a sudden cardiac arrest from a cardiac cause in the
context of a deterioration is difficult, and standard practice is usually to
attempt CPR on any inpatient who has a cardiac arrest, regardless of
the underlying cause.1 Therefore, CPR is often attempted in many
inpatients in whom there is little or no likelihood of benefit, as no
anticipatory decisions were made about resuscitation status.3
Non-maleficence is one of the four pillars of medical ethics and this
principle of ‘do no harm’ is deeply engrained in the attitudes of
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healthcare professionals.4 As such, protecting patients from unnec-
essary and potentially harmful procedures is an important aspect of
healthcare provision. Whilst having the potential to prolong survival in
some, for many patients CPR is at best futile and at worst degrading
and physically harmful to a patient in the dying phase.
Even in successful CPR attempts, the effects of prolonged
cerebral hypoxia can result in neurological deficits and a poor quality of
life, suggesting that CPR may prolong death rather than prolong life.
Due to the vigorous nature of chest compressions, there are also
associated physical harms, including rib fractures, and airway
manipulation may cause tracheal lesions.5
The COVID-19 pandemic has further complicated the challenges
surrounding the decision to perform CPR. As CPR is an aerosol
generating procedure, guidance states that staff undertaking CPR
should be wearing full personal protective equipment (PPE) to reduce
the risk of COVID-19 transmission.6,7 The time taken to don PPE may
delay CPR initiation and the use of bulky protective equipment can
make it difficult to perform CPR with effective technique. Patients
suffering from COVID-19 are most likely to deteriorate due to
respiratory failure and/or sepsis. In an initial case series from Wuhan,
China, the majority of cardiorespiratory arrests in COVID-19 inpatients
were due to respiratory causes with asystole being the common
presenting rhythm, hence long-term survival rates were minimal (3%
survival at 30 days).8 This rate of survival to hospital discharge is far
lower than usual rates seen after in-hospital cardiac arrests in the
United Kingdom.9
Guidance from the National Institute of Health and Care
Excellence during the COVID-19 pandemic has emphasised that a
sensitive discussion should be undertaken in adult patients with
capacity in whom an assessment suggests increased frailty (for
example, a Clinical Frailty Score of 5 or more).10 The possible benefits
and risks of any critical care treatment options, including CPR, and the
possible likely outcomes should be taken into account and form part of
the joint decision-making process. These decisions are particularly
important in terminally ill patients approaching the end of life, either
from a chronic, irreversible disease or an acute, severe illness such as
COVID-19.
A ‘Do Not Attempt Cardiopulmonary Resuscitation’ (DNACPR)
decision is an aspect of care that provides guidance to medical staff
regarding the appropriate course of action in the case of a cardiac
arrest. DNACPR decisions may be put in place in the community
(‘community DNACPR’) or in hospital, but are not legally binding or
signed by the patient or a witness. Importantly, DNACPR decisions
differ from an ‘Advance Decision to Refuse Treatment’ (ADRT), which
is a legally binding document signed by the patient which details which
interventions a patient wishes not to receive in the case that they are
unable to express their preferences, and can include decisions around
CPR.
Historically, treatment limitation decisions have only been
considered in patients where treatment may be futile. Doctors may
be hesitant to initiate these difficult conversations due to fear of
causing distress or complaints.11 However, due to the unpredictable
nature of COVID-19 and who it may affect, at our hospital it was
recommended that a conversation should be initiated with all
inpatients surrounding ceilings of treatment and CPR, and document
the subsequent decision.2
In the UK, many health and social care providers use a
Recommended Summary Plan for Emergency Care and Treatment
(ReSPECT), which documents the response to an emergency with
a summary of recommendations to help make immediate decisions
about a person’s care and treatment.12 The ReSPECT form is
paper-based and many hospitals use this and other paper records
to document decisions during patients’ hospital stays. However, as
Electronic Healthcare Records (EHR) are rolled out in hospitals,
DNACPR and Treatment Escalation and Limitation (TEAL)
decisions are increasingly being documented electronically to
provide high visibility and clear communication of the decisions.13
Our institution has adopted DNACPR within the EHR since October
2011.
This study aims to analyse EHR documentation on treatment
limitation and DNACPR decisions comparing uptake, decisions and
answers to different sections of the form before and during the COVID-
19 situation.
Methods
Institution
This analysis was conducted in a large, urban teaching hospital in the
West Midlands, UK, with an in-house built clinically-led EHR, PICS
(Prescribing, Information and Communication System), which has
been described elsewhere.14 The 1250-bed academic teaching
hospital consists of a staff of over 7000 employees delivering general,
specialist and emergency services to the local population. It has a
large 100-bed intensive care unit with a surge capacity within the
COVID-19 crisis to provide up to 350 critical care beds. There is no
paediatric or obstetric care at the hospital. PICS provides users with
clinical decision support, based on user privilege, full clinical
documentation, provision of clinical protocols and best practice
guidelines.
The PICS EHR incorporated a DNACPR/TEAL status form from
the 17th October 2011 (Fig. 1). This was designed in conjunction with
clinical staff including resuscitation services and palliative care. The
form has mandated and non-mandated questions, and particular
responses open other relevant sections of the form. It commences
with the question ‘would you be surprised if the patient died on this
admission?’ and then continues to ‘is this patient for full active
treatment?’.
Study population
Data was extracted from the PICS audit system for all DNACPR/TEAL
forms completed. Data included the contents of the forms for all
patients admitted between 1st January 2017 and 30th April 2020, as
well as patient demographics. Patients may have multiple copies of
this form as their conditions or situations change over their admission
or on subsequent admissions. Therefore, to understand the differ-
ences in how the forms were completed and in order to avoid
collinearity, only the first form completed for each patient was
considered. The data was split into forms completed prior to 1st March
2020 (pre-COVID) and data between 1st March and 30th April 2020
(during COVID). The data collected during the COVID-19 period is
compared with a corresponding time period in 2019, between 1st
March to 30th April 2019.
To understand the impact on the hospital as a whole, the proportion
of admissions with a valid DNACPR/TEAL status form completed
during the admission was calculated. All patient episode forms in
those who were admitted for at least 24 h were considered in this
analysis.
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Analytical/statistical methods
Data were analysed using Stata 15.1 (StataCorp). Summary counts
and percentages are given for categorical values and median with
interquartile range for continuous variables. Chi-Square analysis was
performed on categorical variables and the Kruskall Wallis test on
continuous variables.
Governance/role of funding source
The work is part of an ongoing institutional audit programme of
DNACPR completion registered with the Clinical Audit Registration &
Management System within the hospital. There was no external
funding for this study.
Results
A total of 16,007 forms were identified during the study period, 14,163
in the pre-COVID period, including 729 from 1st March to 30th April
2019. There were 1844 forms in the COVID period, with the rate of new
forms more than doubling. There was also a marked increase in the
percentage of patients who had spent at least 24 h in the hospital with a
DNACPR/TEAL status documented on the EHR during some of their
admission (Fig. 2).
Where decisions were recorded about resuscitation in a patient
record during the COVID-19 period, patients were younger (79 years
pre-COVID vs 74 years during COVID; p < 0.001), less likely to have
various co-morbidities and less likely to have a referral to the palliative
care team (16.7% vs 28.5%; p < 0.001) (Table 1).
There were several findings that suggest that doctors’ behaviours
changed during the COVID-19 crisis. Not only were significantly more
decisions taken around resuscitation, but questions were answered
differently (Table 2). Specifically, more doctors completing forms
expressed that they would be surprised if patients died during
admission (31.2% vs 17.0%, p < 0.001).
Doctors must state on the form whether CPR would be appropriate
in the event of cardiopulmonary arrest. During COVID-19, significantly
more patients had decisions made that CPR would be appropriate
(23.8% vs 9.05% p < 0.001), reflecting active decision-making taking
place for more patients. Doctors are then asked if the patient should be
for full active treatment, and similarly more cases during COVID-19
were recorded as being for full treatment (30.5% vs 26.1%, p = 0.028).
Of note, these three questions are all independent of each other.
Where a decision was made that treatment should be limited, this
was due to futility in most cases, with the remainder due to patient’s
wishes. Multiple reasons can be chosen, but reasons did not change
significantly during COVID-19. However, there do appear to be fewer
patients during COVID-19 with an advanced decision to refuse
treatment (ADRT) (4.3% vs 1.7%, p = 0.771).
The proportion of discussions that involved the patient remained
similar, with 95.6% in 2019 compared to 95.8% during COVID-19
(p = 0.871). There was an increase in the proportion of patients with
capacity to be involved in decisions (43.9%58.5%, p < 0.001).
However, there was a significant decrease in DNACPR/TEAL
decisions being discussed with the relatives  dropping from
75.4% to 50.6% (p < 0.001).
There was a marginally significant change in when the review
dates (7 days, 28 days or indefinite) were set for reviewing the
DNACPR/TEAL decisions when initially completing the forms.
Patients who had a DNACPR in place during the COVID-19
pandemic were generally younger than in MarchApril 2019 (74.5
years vs 79 years, p = 0.015) and had fewer comorbidities, with the
exception of renal disease which was similar in the two groups
Fig. 1 – Screenshot of DNACPR/TEAL form in EHR.
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(Table 3). The patients who had a form completed but did not have a
DNACPR in place were also younger during COVID-19 than in 2019
(54.5 years vs 61.5 years, p = 0.006).
Information on patients’ preferences regarding treatments and
their limitations can also be captured by the form, although it is not a
compulsory question. During the COVID-19 era, significantly fewer
clinicians completed this question than in 2019 (49.7% vs 56.9%,
p = 0.001.
Discussion
The data would support the notion that clinicians have followed the
recommendations to initiate treatment limitation conversations with
more inpatients during this period. 1844 decisions involving CPR were
made in an eight-and-a-half-week period, compared to 14,163 in the
previous 165 weeks, reflecting an increase in the mean proportion of
inpatients who had a form completed from 20% to 50%.
The National Confidential Enquiry into Patient Outcome and Death
suggested that clear documentation for ceilings of care facilitates early
decision making and improves clarity of intent.3 Nevertheless, it is
apparent from this data that DNACPR forms were previously only
completed in a small minority of patients in whom there is more likely to
be an indication for treatment limitation. This suggests that there was a
shift during the COVID-19 pandemic from undertaking decisions only
in critically ill patients to a much wider group of inpatients. Of patients
with treatment limitation documentation in place, clinicians previously
believed 83% of patients were likely to die during admission in the
similar period in 2019; this decreased to 70% during COVID-19.
Similarly, during the pandemic 30.5% of patients were for full
Fig. 2 – (a) Patterns of form completion before and during the COCID-19 pandemic. (b) Close-up view of COVID-19 period
compared to MarchApril 2019.
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treatment, compared to 26.1% in 2019. This suggests that these
conversations were being had with more patients who were not
thought to be nearing the end of life and so CPR would be appropriate.
This is supported by the fact that during COVID-19, patients who had a
form in place were generally younger, had fewer co-morbidities and
were less likely to have a palliative care referral. This increase in
discussions about treatment limitations with a wider patient group than
usual seems very appropriate during a pandemic period. However, it is
difficult to establish whether the threshold for a DNACPR decision has
changed as there was a parallel increase in both form completion and
DNACPR decisions in younger patients.
Reasons for patients not being for full active treatment were similar
between the two time periods. However significantly fewer patients
had an ADRT during the COVID-19 era, 1.7% compared with 4.3% in
Table 1 – Demographics of patients with a completed form.
Pre-COVID MarApr 2019 During COVID p Valuez
n 14,163 729 1844
Median patient age (IQR) 79 (6787) 79 (6887) 74 (6183) <0.001
Age group (years) Under 66 3199 (22.6%) 160 (21.9%) 595 (32.3%) <0.001
6677 3207 (22.6%) 180 (24.7%) 497 (27.0%)
7884 2810 (19.8%) 142 (19.5%) 345 (18.7%)
8590 2809 (19.8%) 142 (19.5%) 272 (14.8%)
Over 90 2138 (15.1%) 105 (14.4%) 135 (7.3%)
Sex Female 7373 (52.1%) 366 (50.2%) 865 (46.9%) 0.143
Male 6790 (47.9%) 363 (49.8%) 979 (53.1%)
Co-morbidities Cancer 3502 (24.7%) 203 (27.8%) 214 (13.1%) <0.001
Renal disease 2759 (19.5%) 135 (18.5%) 316 (17.1%) 0.439
Congestive Cardiac Failure 2694 (19.0%) 119 (16.3%) 189 (10.3%) <0.001
Liver Failure 362 (2.6 %) 17 (2.3 %) 15 (0.8 %) 0.003
Palliative Care 3816 (26.9%) 208 (28.5%) 308 (16.7%) <0.001
Critical Care 502 (3.5%) 19 (2.6%) 62 (3.4%) 0.387
SEWSyy Risk SEWS 0 4847 (34.2%) 255 (35.4%) 549 (29.8%) 0.012
Low SEWS 7056 (49.8%) 334 (45.8%) 959 (52.0%)
Medium SEWS 1287 (9.1%) 79 (10.8%) 196 (10.6%)
High SEWS 625 (4.4%) 53 (7.3%) 103 (5.6%)
Missing SEWS Information 348 (2.5%) 8 (1.1%) 37 (2.0%)
Median Length of Stay (IQR) (Days)y 14 (627) 14(628) 6 (313) <0.001
Patient status at dischargey Alive 9627 (68.0%) 505 (69.5%) 1290 (77.3%) <0.001
Deceased 4531 (32.0%) 222 (30.5%) 378 (22.7%)
y This is only given for the patients who have been discharged when the study was completed.
yySEWS — Standardised Early Warning Scoring system.
z This P value compares the COVID period to those forms completed in March and April 2019.
Table 2 – Responses on the DNACPR/TEAL form on the PICS EHR.
Pre-COVID MarApr 2019 During COVID p Valuez
Completion (total N) 14,163 729 1844
Doctor would be surprised if patient died on this admission 2183 (15.4%) 124 (17.0%) 575 (31.2%) <0.001
DNACPR is in place 12,650 (89.3%) 663 (90.9%) 1406 (76.3%) <0.001
Patient is for full active treatment 3864 (27.3%) 190 (26.1%) 563 (30.5%) 0.028
Reason not for full active treatmenty Patient’s wishes known 2079 (20.2%) 105(19.5%) 242 (18.9%) 0.107
Futility 9174 (89.1%) 469(87.0%) 1143 (89.2%) 0.076
ADRT 329 (3.2%) 23(4.3%) 22 (1.7%) 0.711
Patient has capacity to be involveda 5729 (44.6%) 296 (43.9%) 839 (58.5%) <0.001
Decision was discussed with patientb 5300 (92.5%) 283 (95.6%) 804 (95.8%) 0.871
Decision was discussed with relativesc 8520 (70.3%) 480 (75.4%) 648 (50.6%) <0.001
Review date1 7 days: 43.6% 7 days: 42.4% 7 days: 42.4% 0.133
28 days: 20.2% 28 days: 19.7% 28 days: 23.1%
Indefinite: 36.4% Indefinite: 37.9% Indefinite: 34.4%
a This is only completed when the patient is either not for full active treatment or not for active CPR (n = 15,826).
b This question is only answered when it is confirmed that the patient has the mental capacity to be involved in decisions (n = 6568).
c This is only completed when the patient has either given consent for their conditions to be discussed with relatives or does not have the mental capacity to be
involved in decisions (n = 13,405).
y Only for those who are not for full active treatment and multiple options can be chosen per patient.
z This P value compares the COVID period to those forms completed in March and April 2019.
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2019. It is unclear whether this is a true lack of advanced decision
making or purely a lack of communication of any advanced directive
during this crisis period. It may also reflect the younger, fitter cohort
who are less likely to have an ADRT in place.
Shared decision making is a concept that has grown in popularity in
recent times.15 Discussions around ceilings of care should involve
patients where possible, and people should be included in decisions
about their care.16 The proportion of discussions that involved the
patient was roughly similar. However, significantly more patients were
deemed to have capacity, increasing from 43.9% to 58.5%. This is
possibly due to the change from traditional practice of only initiating
decisions when patients are either extremely frail, and may have lost
capacity due to their disease or comorbidities, or are already too
critically ill to be communicated with. Despite the change in
circumstances since COVID-19, it appears that doctors are still
involving patients in these key decisions where possible. Including
patients in discussions about their care allows them to clarify what their
preferences are with regards to ceilings of care and treatment
escalation.
Patients’ preferences continue to be documented; there has been
a small decrease from 56.9% to 49.7% of clinicians documenting
patient wishes. There is a shift from patients prioritising comfort to
opting for life-sustaining treatments as shown in Fig. 3. As previously
discussed, this may be due to an increase in these conversations with
relatively well patients who are younger and therefore more likely to
want full life-sustaining treatment. It is important to note that
documenting patient wishes is not mandatory in the electronic form,
thus explaining the overall low percentage of completion. Over 90% of
decisions were discussed with the patient, therefore patient wishes
may be considered but not explicitly documented in this form.
Especially during times of increased pressure on clinicians’ time, non-
compulsory questions are likely to be ignored Documenting patient
preferences should be encouraged to ensure that there is a shared
understanding of where the balance between active medical
interventions and comfort care is considered appropriate.
Patients may normally choose to involve their families in
discussions surrounding ceilings of care. To reduce the spread of
COVID-19 and maintain social distancing, during the pandemic
Table 3 – Age and comorbidities of patients before and during COVID-19 and whether they had a DNACPR put in place
or not.
Pre-COVID MarApr 2019 During COVID p Valuez
DNACPR is in place 12,650 (89.3%) 663 (90.9%) 1406 (76.3%) <0.001
Patients with DNACPR in place Median patient age (IQR) 81 (7088) 79 (6987.3) 74.5 (63.382) 0.015
Cancer 3215 (25.4%) 191 (28.8%) 212 (15.1%) <0.001
Renal disease 2630 (20.8%) 132 (19.9%) 286 (20.3%) 0.819
Congestive Cardiac Failure 2543 (20.1%) 116 (17.5%) 175 (12.4%) 0.002
Liver Failure 340 (2.7%) 17 (2.6%) 12 (0.9%) 0.003
Patients without DNACPR in place Median patient age (IQR) 58 (4370) 61.5 (4575) 54.5 (4465) 0.006
Cancer 287 (19.0%) 12 (18.2%) 29 (6.6%) 0.006
Renal disease 129 (1.0%) 3 (0.5%) 30 (2.1%) 0.349
Congestive Cardiac Failure 151 (1.2%) 3 (0.5%) 14 (1.0%) 0.389
Liver Failure 22 (0.2%) 0 (0.0%) 3 (0.2%) 0.656
z This P value compares the COVID period to those forms completed in March and April 2019.
Fig. 3 – Patient preferences on treatment priorities.
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visitors were no longer allowed in our hospital, apart from exceptional
circumstances. This may explain the reduction in discussions with
relatives from 75.4% to 50.6%, as they are no longer available for face-
to-face discussions. Our experience suggested that treatment
limitation discussions did tend to take place during patient admissions
with their relatives by telephone as we employed dedicated family
liaison personnel. However, these discussions were noted in the
narrative patient record and not revisited on the DNACPR/TEAL
status form. It is also possible that as a smaller proportion of patients
are having decisions advising treatment limitation, that clinicians may
decide that the decisions do not need to be discussed with the family,
as full active treatment would be the care they would expect.
Although there is a statistically significant difference between the
review date set between the pre-COVID era and during the pandemic,
this may not be clinically significant as proportions were not dissimilar.
Without greater scrutiny into the decision-making process of
clinicians, it is difficult to establish the justifications for review date
decisions.
We are quite reassured by the apparent change in practice during
the COVID-19 pandemic and recognise that making early decisions
surrounding ceilings of care has multiple benefits. Patients and their
families are prepared for the possibility of deterioration, giving them
time to consider their wishes and concerns, and thus allowing patient
autonomy, which is particularly important to remember in a time of
such uncertainty. In-hospital CPR is managed by a team of healthcare
professionals and during the COVID-19 situation, where healthcare
systems are under increased pressure, the inappropriate initiation of
CPR may remove critical care staff from other patients where their
expertise may be more beneficial. Furthermore, PPE is a precious
resource in this time,17 and it is therefore important to minimize
potential ‘wastage’ by avoiding inappropriate CPR.
Study limitations
There are some limitations to this study. The information submitted on
the electronic form is only what is reported at the time. It is possible that
due to social responsibility bias that what was said to happen
(discussion with patient and/or relatives) may not have actually
happened. As with any electronic form it is impossible to uncover these
responses, however we cannot see why COVID-19 would have
considerably affected the rate of such responses. We only addressed
the first DNACPR/TEAL form for each patient to prevent double
counting responses. However, if a patient had several admissions
during the time period, with different decisions on the DNACPR/TEAL
this would have been missed. Clinicians can re-enter and change the
forms as many times as they like within an episode. Therefore, we
miss the nuances of data if clinicians have altered forms when, for
example, relatives have been communicated with at a later stage. Our
experience tells us that even when communication by telephone
happens with relatives, that people usually document this in the noting
section of the EHR and do not re-enter the DNACPR/TEAL form itself.
Lastly, despite the positive response to early senior decision making in
the COVID-19 pandemic, we will have to collect ongoing data to see if
this effect is sustained in the postCOVID period.
Conclusion
Decisions about cardiopulmonary resuscitation and treatment
escalation are a key part of modern hospital care. Whilst the main
clinical focus should always be on prevention of cardiac arrest 
which is the first link in the chain of survival18  there are inevitable
cases where sudden unexpected deterioration requires institution of
life support. However, avoiding unnecessary CPR attempts which
would lead to a degrading situation at the end of life, is also key. Whilst
there should be a discussion about all inpatients surrounding
treatment limitation or escalation, evidence remains that this does
not always occur. It is heartening to see that DNACPR/TEAL decisions
are being made in a greater proportion of patients. We hope that the
attitudinal changes seen persist after COVID-19 to provide ongoing
patient-centred decision making and avoid potentially futile CPR
attempts in the future.
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